查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853779

按产品类型、应用和最终用户分類的微型RNA市场—2025-2032年全球预测

microRNA Market by Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年， 微型RNA市场规模将达到 218.5 亿美元，复合年增长率为 29.72%。

关键市场统计数据
基准年 2024 27.2亿美元
预计年份：2025年 35.4亿美元
预测年份 2032 218.5亿美元
复合年增长率 (%) 29.72%

权威地介绍了微型RNA的生物学、转化潜力、实行技术以及在研究和临床环境中的战略意义。

微型RNA生物学已从最初的学术研究发展成为分子调控的核心支柱，对研究、诊断和治疗开发产生了深远的影响。这些短链非编码RNA在多种生物系统中调控转录后基因表达，其失调与肿瘤发生、心血管疾病、感染疾病反应和神经退化疾病等密切相关。随着研究人员和临床医生对微型RNA网路的理解不断加深，相关技术也随之发展，提供了灵敏、特异性且可扩展的检测方法，为基础科学和转化医学研究提供了重要资讯。

因此，学术界、诊断学界和产业界的相关人员现在都将微型RNA分析视为发现新药的引擎和实现近期临床应用的途径。高通量定序、标靶扩增技术和先进生物资讯学的融合降低了技术门槛，并催生了从群体层级生物标记筛选到单细胞和空间分辨研究等新型研究设计。因此，投资重点正转向将稳健的湿实验室工作流程与能够处理多模态数据和符合监管要求的报告的分析平台相结合的整合解决方案，从而将机制性见解转化为可操作的临床和商业性成果。

定序的进步、高灵敏度检测、整合生物资讯学以及合作商业化模式将彻底改变微型RNA的研究和应用。

在技​​术创新和不断变化的临床需求的双重驱动下，近年来微型RNA科学的研究和应用方式发生了变革性转变。定序技术的普及使得对小RNA物种的覆盖范围更广，并提高了对异构体和修饰的区分能力。同时，精准扩增平台、标靶捕获流程和混合方法提高了生物体液中低丰度微型RNA的检测灵敏度，为微创诊断开闢了道路。计算生物学的同步发展，包括机器学习主导的特征选择和整合多组体学框架，正在提升微型RNA特征的可解释性和临床相关性。

除了仪器和演算法之外，产业结构的变化也显而易见。合作开发模式正在伙伴关係，仪器供应商、试剂开发商、生物资讯学提供者和临床实验室之间的合作日益紧密，以加快检验和商业化进程。监管机构正在明确其对核酸检测的要求，而支付方也开始要求提供更有力的临床效用和成本效益证据。总而言之，这些变化正在加速微型RNA发现向标准化检测和决策支援工具的转化，同时也提高了资料品质、可重复性和合规性方面的要求。

评估2025年美国关税将如何改变微型RNA研究和诊断领域的供应链、筹资策略和营运重点。

美国2025年宣布的关税措施的累积效应，为整个微型RNA生态系统带来了复杂的营运和策略压力。进口设备、关键试剂和专用耗材的关税提高了到岸成本，并使实验室和诊断开发商的采购週期更加复杂。这些压力导致依赖全球供应链的学术机构、合约研究组织和诊断实验室的前置作业时间延长，资本支出和营运成本增加。对于依赖跨境生产精密光学元件、微流体元件和专用酵素的供应商而言，关税正在造成利润率压力，迫使他们重新评估定价策略和生产地点。

为因应新的关税环境，各公司正采取缓解策略，包括供应商多元化、扩大区域製造伙伴关係以及实施库存和合约避险。一些相关人员正在加快关键零件的国产化进程，或对替代化学品和平台进行认证，以减少对受关税影响的进口产品的依赖。同时，由于采购限制导致设备部署和试剂供应延迟，研发週期可能会延长，合作计划也需要修改合约以反映更高的整体成本。总体而言，这将导致计划预算和优先排序方式转变，鼓励企业开展能够快速提供技术检验和明确临床价值的项目，以在成本动态的情况下证明调整后的投资水平的合理性。

关键细分洞察揭示了产品类型、应用领域和最终用户群如何决定产品采用路径和检验优先顺序。

对产品、应用和最终用户细分的深入理解揭示了微型RNA价值链中存在的差异化机会和执行挑战。在产品层面，这包括仪器、套件、试剂、软体和服务。仪器包括微阵列系统、qPCR系统和定序系统，每种系统都有不同的灵敏度和通量特性。套件和试剂包括检测试剂套件、萃取试剂套件、样品製备试剂套件和分析试剂套件，每种试剂盒都针对不同的样品类型和工作流程。软体和服务包括生物资讯服务、咨询服务和数据分析软体，弥合了从原始数据到可操作解读之间的鸿沟。这些产品层面的差异影响着最终使用者的采用模式、检验需求和采购标准。

从应用角度来看，其能力可分为基础研究、诊断以及药物发现与发展。在基础研究领域，功能基因组学和基因表现分析等活动依赖灵活的平台，这些平台优先考虑广度和实验控制。在诊断应用方面，重点在于癌症、心血管疾病和感染疾病的诊断，这需要标准化的通讯协定、临床检验和法规遵循。在药物发现与开发方面，重点在于生物标记发现、标靶验证和毒性测试，其中可重复性、实验室间可比性以及与其他临床前数据集的整合至关重要。最终用户细分进一步明确了学术和研究机构、合约研究组织、诊断实验室以及製药和生物技术公司的营运需求和采购行为，每个机构都有其独特的采购週期、检验阈值和服务期望。了解这些细分领域的交集，有助于供应商根据特定的客户需求和监管时间表，调整产品设计、支援服务和商业化路径。

从区域战略观点出发，重点在于阐述美洲、欧洲、中东和非洲以及亚太地区各自如何影响技术采纳、监管策略和商业化路径。

区域动态对微型RNA倡议的采纳、商业化和营运执行有显着影响。在美洲，强大的学术网络、蓬勃发展的生物技术产业和活跃的临床试验基础设施加速了转化计划的推进，但各机构必须应对不断变化的报销框架和供应链突发情况。欧洲、中东和非洲的情况则较为复杂，先进的监管体系和公共卫生优先事项与製造能力和采购惯例的差异并存。亚太地区展现出快速的技术采纳、对本地製造的大量投资以及不断增长的诊断服务网络，但相关人员面临着监管方式的多样性和本地供应商的竞争，这些都可能影响伙伴关係策略。

这些区域格局会影响企业优先考虑的监管申报、本地生产投资和策略伙伴关係。例如，在临床基础设施和报销机製成熟的地区，技术推广速度往往最快；而诊断网络尚处于发展初期的市场可能更倾向于低成本、高通量的平台和分散式工作流程。儘管跨境合作和多中心临床研究仍然是产生广泛相关证据的重要机制，但区域政策的变化，尤其是在资料管治、进口关税和实验室认证方面的政策变化，可能会加速或限制计画的部署。因此，有效的区域策略需要在重点检验工作和反映监管、报销和供应链实际情况的区域特定商业化计画之间取得平衡。

竞争与合作：公司层面的动态表明，平台性能、试剂品质、生物资讯能力和服务整合将决定微型RNA倡议的成功。

微型RNA生态系统内的竞争格局反映了成熟仪器製造商、敏捷的试剂创新者、专业的生物资讯公司和综合服务供应商的整合。仪器供应商在灵敏度、动态范围和通量等分析性能方面展开竞争，而试剂开发商则在稳健性、批间一致性和易于整合到自动化工作流程方面展开竞争。软体和服务供应商透过提供检验的流程、监管文件和解读层来创造价值，这些解读层可以将复杂的资料集转化为具有临床意义的输出结果。同时，委外研发机构和诊断实验室正在透过提供端到端服务来整合自身能力，从而加速转化检测的验证和市场准入。

平台供应商寻求与套件和试剂专家合作，以提供检验的工作流程；生物资讯公司与临床实验室合作，以在真实环境中优化演算法；製药公司与外部服务供应商合作，以降低生物标誌物发现和检验工作的风险。这些模式有利于那些能够展现互通性、符合法规要求和扩充性的机构。此外，投资于标准化资料模型和透明检验方法的公司更有能力支持跨中心研究，并满足临床医生和付款方的证据要求。

为领导者提供切实可行的策略建议，以增强供应链韧性、实施模组化工作流程、优先考虑生物资讯学并加快符合监管要求的验证。

产业领导者应采取务实的多管齐下策略，兼顾短期韧性和长期价值创造。首先，透过对关键组件的多个供应商进行资格认证、探索区域製造伙伴关係关係以及为高优先级试剂和耗材维持战略安全库存，来增强供应链韧性。其次，优先投资于模组化、基于标准的流程，以实现仪器平台和试剂化学之间的快速切换，从而减少供应商锁定并加快跨站点的验证。第三，透过采用可互通的数据标准、投资于可重复的流程以及建立临床级报告模组来加强生物资讯学和数据管理能力，从而促进监管申报和临床医生的应用。

后续步骤包括深化学术界、临床实验室和产业界之间的伙伴关係，共同开发满足科学和监管需求的检验检测方法；实施灵活的商业模式，例如试剂即服务和奖励式检测，以使激励机制与最终用户保持一致。最后，审查定价和合约框架，以反映关税主导的成本动态，同时透过临床效用和营运效率的证据透明地传达价值。这些综合措施将有助于企业保护利润率，保持创新步伐，并提高临床应用和商业化的成功率。

采用稳健的混合调查方法，结合文献综合、专家访谈、绩效检验和三角测量，以确保得出站得住脚且可操作的结论。

本分析的调查方法结合了对原始科学文献的结构化回顾、对来自学术界、工业界和临床实验室的专家进行的定向访谈，以及将技术性能特征与独立检验报告和监管指导文件进行交叉检验。该方法包括系统地梳理仪器功能、试剂性能参数和软体互通性，然后进行情境分析，以评估在不同采购和监管条件下的运作影响。在条件允许的情况下，研究结果透过多方面的证据进行三角验证，以确保其稳健性并揭示一致的模式，而非孤立的观察。

品质保证措施包括：根据独立的检测性能数据检验技术声明；审查临床试验註册资讯以获取转化证据；以及与实验室主任和采购主导者协商，以确保结果与实践相关。调查方法强调假设的透明度、分析步骤的可重复性，以及使用分析灵敏度、特异性和临床验证等关键术语的标准定义，从而确保研究、诊断和商业运作中的决策者能够采纳并支持研究结论。

总结全文，重点阐述技术进步、营运灵活性和策略伙伴关係关係如何融合，从而释放微型RNA的转化和商业性潜力。

总之， 微型RNA领域正处于曲折点，科学成熟度、技术能力和商业性机会在此交汇融合。检测技术、定序深度和计算分析的进步，使得更可靠的生物标记发现和诊断方法的开发成为可能；同时，采购和法规环境的变化也迫使我们更灵活地运作。积极应对供应链中断、优先考虑可互通和检验的工作流程，并投资于临床级生物资讯学的利益相关人员，将更有能力将科学发现转化为有效的诊断和治疗方法。

透过将技术蓝图与监管和报销现实相协调，促进伙伴关係关係以加速对各种样本类型和用例的检验，并实施采购和商业策略以降低关税和供应风险，各组织可以保持创新势头，加快临床影响的时间，并获得微型RNA科学为患者和研究界带来的切实利益。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 基于微型RNA的液态生物检体检测方法因其高特异性，在癌症早期检测中的应用日益广泛。
  • 开发针对肝纤维化路径的合成微型RNA疗法以实现精准医疗
  • 整合自动化微型RNA萃取和定量平台以提高实验室通量
  • 用于心血管疾病进展和风险分层个人化监测的新兴微型RNA生物标记
  • 增加对微型RNA递送载体的投资，以增强其体内稳定性和目标组织吸收。
  • 扩展微型RNA谱分析服务，以支援临床研究中的药物发现和生物标记检验
  • 多重微型RNA定序技术的创新使得低成本的全面转录组分析成为可能。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按产品类型分類的微型RNA市场

  • 装置
    • 微阵列系统
    • qPCR系统
    • 定序系统
  • 套件和试剂
    • 检测套件
    • 提取套件
    • 样品製备套件
    • 分析套件
  • 软体和服务
    • 生物资讯服务
    • 咨询服务
    • 数据分析软体

第九章 按应用分類的微型RNA市场

  • 基础研究
    • 功能基因体学
    • 基因表现分析
  • 诊断
    • 癌症诊断
    • 心血管诊断
    • 感染疾病诊断
  • 药物发现与开发
    • 生物标记发现
    • 目标检验
    • 毒理学研究

第十章 以最终用户分類的微型RNA市场

  • 学术研究机构
  • 合约研究组织
  • 诊断实验室
  • 製药和生物技术公司

第十一章 各地区的微型RNA市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章微型RNA市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国微型RNA市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Illumina, Inc.
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bio-Rad Laboratories, Inc.
    • Merck KGaA
    • Promega Corporation
    • NanoString Technologies, Inc.
    • Takara Bio Inc.
Product Code: MRR-02026C4C98C4

The microRNA Market is projected to grow by USD 21.85 billion at a CAGR of 29.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.72 billion
Estimated Year [2025] USD 3.54 billion
Forecast Year [2032] USD 21.85 billion
CAGR (%) 29.72%

An authoritative introduction to microRNA biology, translational potential, enabling technologies, and strategic implications across research and clinical environments

MicroRNA biology has matured from a niche academic curiosity into a central pillar of molecular regulation with profound implications for research, diagnostics, and therapeutic development. These short, non-coding RNA species govern post-transcriptional gene regulation across diverse biological systems, and their dysregulation links directly to oncogenesis, cardiovascular pathology, infectious disease response, and neurodegenerative processes. As investigators and clinicians deepen their understanding of microRNA networks, the technology landscape has adapted to deliver increasingly sensitive, specific, and scalable detection modalities that inform both basic science and translational pipelines.

Consequently, stakeholders across academia, diagnostics, and industry now view microRNA analytics as both a discovery engine and a route to near-term clinical impact. The convergence of high-throughput sequencing, targeted amplification technologies, and advanced bioinformatics has lowered technical barriers and enabled new study designs, from population-level biomarker screens to single-cell and spatially resolved interrogations. As a result, investment priorities are shifting toward integrated solutions that pair robust wet-lab workflows with analytics platforms capable of handling multimodal data and regulatory-grade reporting, thereby turning mechanistic insights into actionable clinical and commercial outcomes.

Critical transformative shifts in microRNA research and application driven by sequencing advances, sensitive detection, bioinformatics integration, and collaborative commercialization models

Recent years have witnessed transformative shifts that are redefining how microRNA science is pursued and applied, driven by both technological innovation and evolving clinical needs. Sequencing technologies have become more accessible and nuanced, enabling deeper coverage of small RNA species and improved discrimination of isoforms and modifications. At the same time, precision amplification platforms, targeted capture workflows, and hybrid approaches have increased sensitivity for low-abundance microRNAs in biofluids, widening the possibilities for minimally invasive diagnostics. Parallel advances in computational biology, including machine learning-driven feature selection and integrative multi-omics frameworks, have increased the interpretability and clinical relevance of microRNA signatures.

Beyond instruments and algorithms, structural industry shifts are also evident. Collaboration models are evolving, with instrument vendors, reagent developers, bioinformatics providers, and clinical labs forming closer partnerships to expedite validation and commercialization. Regulatory agencies are clarifying expectations for nucleic acid-based assays, and payers are beginning to demand stronger evidence of clinical utility and cost-effectiveness. Taken together, these changes are accelerating the translation of microRNA discoveries into standardized assays and decision-support tools, while also raising the bar for data quality, reproducibility, and regulatory compliance.

Assessing how 2025 United States tariff measures are reshaping supply chains, procurement strategies, and operational priorities across the microRNA research and diagnostic landscape

The cumulative effect of United States tariff actions announced in 2025 has introduced a complex set of operational and strategic pressures across the microRNA ecosystem. Tariffs on imported instruments, critical reagents, and specialized consumables increase landed costs and complicate procurement cycles for laboratories and diagnostic developers. These pressures translate into longer lead times and higher capital and operating expenditures for academic institutions, contract research organizations, and diagnostic laboratories that depend on global supply chains. For vendors that rely on cross-border manufacturing of precision optics, microfluidic components, or specialty enzymes, tariffs create margin pressure and force reassessment of pricing strategies and production footprints.

In response to the new tariff environment, organizations are adopting mitigation strategies that include diversifying suppliers, expanding regional manufacturing partnerships, and implementing inventory and contract hedging practices. Some stakeholders are accelerating initiatives to localize critical components or to qualify alternative chemistries and platforms that reduce dependency on tariff-impacted imports. Meanwhile, research timelines can lengthen as procurement constraints delay instrument deployments and reagent availability, and collaborative projects may require revised contracting to reflect higher total costs. The aggregate impact is a shift in how project budgets are structured and prioritized, encouraging initiatives that deliver rapid technical validation and clear clinical value to justify adjusted investment levels under changed cost dynamics.

Key segmentation insights revealing how product types, application domains, and distinct end-user groups jointly determine adoption pathways and validation priorities

A granular understanding of product, application, and end-user segmentation reveals differentiated opportunities and execution challenges across the microRNA value chain. From a product perspective, the landscape spans instruments, kits and reagents, and software and services. Instrumentation includes microarray systems, qPCR systems, and sequencing systems, each offering distinct sensitivity profiles and throughput characteristics; kits and reagents comprise detection kits, extraction kits, library preparation kits, and profiling kits that are tailored to different sample types and workflows; and software and services encompass bioinformatics services, consultation services, and data analysis software that bridge raw data to actionable interpretation. These product-level distinctions shape adoption patterns, validation needs, and procurement criteria for end users.

In terms of application, functions bifurcate into basic research, diagnostics, and drug discovery and development. Within basic research, activities such as functional genomics and gene expression profiling rely on flexible platforms that prioritize breadth and experimental control. Diagnostic applications emphasize cancer diagnostics, cardiovascular diagnostics, and infectious disease diagnostics, requiring standardized protocols, clinical validation, and regulatory readiness. Drug discovery and development efforts concentrate on biomarker discovery, target validation, and toxicology studies, where reproducibility, cross-laboratory comparability, and integration with other preclinical datasets are paramount. End-user segmentation further clarifies operational demands and purchasing behaviors, encompassing academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotechnology companies, each with unique procurement cycles, validation thresholds, and service expectations. Recognizing how these segments intersect enables providers to align product design, support services, and commercialization pathways to specific customer needs and regulatory timelines.

Regional strategic perspectives highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific each shape adoption, regulatory strategy, and commercialization pathways

Regional dynamics materially influence the adoption, commercialization, and operational execution of microRNA initiatives. In the Americas, strong academic networks, a robust biotech industry, and active clinical trial infrastructures accelerate translational projects, but organizations must navigate evolving reimbursement frameworks and supply chain contingencies. Europe, Middle East & Africa presents a heterogeneous landscape where advanced regulatory ecosystems and public health priorities coexist with variable manufacturing capacity and procurement practices; opportunities often arise from pan-European consortia and region-wide clinical validation initiatives that harmonize standards. Asia-Pacific demonstrates rapid technology uptake, significant investment in local manufacturing, and growing diagnostic service networks, yet stakeholders contend with diverse regulatory approaches and competitive local suppliers that can influence partnership strategies.

These regional contours affect where companies prioritize regulatory submissions, localized manufacturing investments, and strategic partnerships. For example, adoption timelines tend to be fastest where clinical infrastructure and reimbursement pathways are mature, whereas markets with emerging diagnostic networks may favor lower-cost, high-throughput platforms and decentralized workflows. Cross-border research collaborations and multicenter clinical studies remain essential mechanisms for generating broadly relevant evidence, and regional policy shifts-particularly around data governance, import tariffs, and laboratory accreditation-can accelerate or constrain planned rollouts. Effective regional strategies therefore balance centralized validation efforts with localized commercialization plans that reflect regulatory, reimbursement, and supply chain realities.

Competitive and collaborative company-level dynamics showing how platform performance, reagent quality, bioinformatics capabilities, and service integration determine success in microRNA initiatives

Competitive dynamics within the microRNA ecosystem reflect a blend of established instrument manufacturers, agile reagent innovators, specialized bioinformatics houses, and integrated service providers. Instrument vendors differentiate through analytical performance characteristics such as sensitivity, dynamic range, and throughput, while reagent developers compete on robustness, lot-to-lot consistency, and ease of integration into automated workflows. Software and services providers create value by offering validated pipelines, regulatory-ready documentation, and interpretive layers that turn complex datasets into clinically meaningful outputs. Simultaneously, contract research organizations and diagnostic laboratories are consolidating capabilities around end-to-end service offerings that accelerate validation and market entry for translational assays.

Strategic activity in the sector tends to focus on pairing complementary strengths: platform vendors seek partnerships with kit and reagent specialists to deliver validated workflows; bioinformatics firms collaborate with clinical labs to refine algorithms under real-world conditions; and pharmaceutical companies engage with external service providers to de-risk biomarker discovery and validation efforts. These patterns favor organizations that can demonstrate interoperability, regulatory diligence, and scalability. Additionally, firms that invest in standardized data models and transparent validation practices are better positioned to support cross-institutional studies and to meet the evidentiary demands of clinicians and payers alike.

Actionable strategic recommendations for leaders to build supply chain resilience, deploy modular workflows, prioritize bioinformatics, and accelerate regulatory-ready validation

Industry leaders should adopt a pragmatic, multi-pronged strategy that balances near-term resilience with long-term value creation. First, expand supply chain resilience by qualifying multiple suppliers for critical components, exploring regional manufacturing partnerships, and maintaining strategic safety stocks for high-priority reagents and consumables. Second, prioritize investments in modular, standards-compliant workflows that allow rapid switching between instrument platforms and reagent chemistries, thereby reducing vendor lock-in and accelerating validation across sites. Third, strengthen bioinformatics and data management capabilities by adopting interoperable data standards, investing in reproducible pipelines, and building clinical-grade reporting modules that facilitate regulatory submissions and clinician adoption.

Further actions include deepening partnerships across academia, clinical laboratories, and industry to co-develop validation studies that meet both scientific and regulatory needs, and implementing flexible commercial models such as reagent-as-a-service or subscription-based analytics to align incentives with end users. Finally, reassess pricing and contracting frameworks to reflect tariff-driven cost dynamics while transparently communicating value through evidence of clinical utility and operational efficiency. Together, these measures help organizations protect margins, preserve innovation velocity, and improve the probability of successful clinical translation and commercialization.

Robust mixed-methods research methodology combining literature synthesis, expert interviews, performance validation, and triangulation to ensure defensible and actionable conclusions

The research methodology underpinning this analysis combined a structured review of primary scientific literature, targeted interviews with domain experts across academia, industry, and clinical laboratories, and cross-validation of technology performance characteristics against independent validation reports and regulatory guidance documents. The approach included systematic mapping of instrument capabilities, reagent performance parameters, and software interoperability, followed by scenario analysis to evaluate operational impacts under alternative procurement and regulatory conditions. Wherever possible, findings were triangulated across multiple evidence streams to ensure robustness and to surface consistent patterns rather than one-off observations.

Quality assurance measures encompassed validation of technical claims against independent assay performance data, review of clinical trial registries for translational evidence, and consultations with laboratory directors and procurement leads to ground results in operational realities. The methodology emphasized transparency in assumptions, reproducibility of analytic steps, and the use of standard definitions for key terms such as analytical sensitivity, specificity, and clinical validation, thereby ensuring that conclusions remain actionable and defensible for decision-makers across research, diagnostic, and commercial functions.

Conclusive synthesis emphasizing how technological advances, operational agility, and strategic partnerships converge to unlock microRNA's translational and commercial potential

In conclusion, the microRNA landscape stands at an inflection point where scientific maturity, technological capability, and commercial opportunity intersect. Advances in detection technologies, sequencing depth, and computational analytics are enabling higher-confidence biomarker discovery and more reliable diagnostic development, while changing procurement and regulatory environments demand greater operational agility. Stakeholders that proactively adapt to supply chain disruptions, prioritize interoperable and validated workflows, and invest in clinical-grade bioinformatics will be well positioned to translate scientific insights into validated diagnostics and therapeutics.

The imperative for leaders is clear: align technical roadmaps with regulatory and reimbursement realities, cultivate partnerships that accelerate validation across diverse sample types and use cases, and implement procurement and commercial strategies that mitigate tariff and supply risks. By doing so, organizations can preserve innovation momentum, reduce time-to-clinical-impact, and capture the tangible benefits of microRNA science for patients and research communities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of microRNA-based liquid biopsy assays for early cancer detection with high specificity
  • 5.2. Development of synthetic microRNA therapeutics targeting hepatic fibrotic pathways for precision medicine
  • 5.3. Integration of automated microRNA extraction and quantification platforms to improve laboratory throughput
  • 5.4. Emergence of microRNA biomarkers for personalized monitoring of cardiovascular disease progression and risk stratification
  • 5.5. Growing investment in microRNA delivery vectors for enhanced in vivo stability and targeted tissue uptake
  • 5.6. Expansion of microRNA profiling services in clinical research to support drug discovery and biomarker validation
  • 5.7. Innovations in multiplexed microRNA sequencing technologies enabling comprehensive transcriptomic analysis at reduced cost

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. microRNA Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Microarray Systems
    • 8.1.2. qPCR Systems
    • 8.1.3. Sequencing Systems
  • 8.2. Kits & Reagents
    • 8.2.1. Detection Kits
    • 8.2.2. Extraction Kits
    • 8.2.3. Library Prep Kits
    • 8.2.4. Profiling Kits
  • 8.3. Software & Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Consultation Services
    • 8.3.3. Data Analysis Software

9. microRNA Market, by Application

  • 9.1. Basic Research
    • 9.1.1. Functional Genomics
    • 9.1.2. Gene Expression Profiling
  • 9.2. Diagnostics
    • 9.2.1. Cancer Diagnostics
    • 9.2.2. Cardiovascular Diagnostics
    • 9.2.3. Infectious Disease Diagnostics
  • 9.3. Drug Discovery & Development
    • 9.3.1. Biomarker Discovery
    • 9.3.2. Target Validation
    • 9.3.3. Toxicology Studies

10. microRNA Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Diagnostic Laboratories
  • 10.4. Pharmaceutical & Biotechnology Companies

11. microRNA Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. microRNA Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. microRNA Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Thermo Fisher Scientific Inc.
    • 14.3.2. QIAGEN N.V.
    • 14.3.3. Illumina, Inc.
    • 14.3.4. Agilent Technologies, Inc.
    • 14.3.5. F. Hoffmann-La Roche Ltd.
    • 14.3.6. Bio-Rad Laboratories, Inc.
    • 14.3.7. Merck KGaA
    • 14.3.8. Promega Corporation
    • 14.3.9. NanoString Technologies, Inc.
    • 14.3.10. Takara Bio Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MICRORNA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MICRORNA MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MICRORNA MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MICRORNA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MICRORNA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS MICRORNA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL MICRORNA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MICRORNA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. MICRORNA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. MICRORNA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MICRORNA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MICRORNA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MICRORNA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MICRORNA MARKET SIZE, BY QPCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MICRORNA MARKET SIZE, BY QPCR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MICRORNA MARKET SIZE, BY QPCR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MICRORNA MARKET SIZE, BY QPCR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MICRORNA MARKET SIZE, BY QPCR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MICRORNA MARKET SIZE, BY QPCR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MICRORNA MARKET SIZE, BY DETECTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MICRORNA MARKET SIZE, BY DETECTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MICRORNA MARKET SIZE, BY DETECTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MICRORNA MARKET SIZE, BY DETECTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MICRORNA MARKET SIZE, BY DETECTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MICRORNA MARKET SIZE, BY DETECTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MICRORNA MARKET SIZE, BY EXTRACTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MICRORNA MARKET SIZE, BY EXTRACTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MICRORNA MARKET SIZE, BY EXTRACTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MICRORNA MARKET SIZE, BY EXTRACTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MICRORNA MARKET SIZE, BY EXTRACTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MICRORNA MARKET SIZE, BY EXTRACTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MICRORNA MARKET SIZE, BY LIBRARY PREP KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MICRORNA MARKET SIZE, BY LIBRARY PREP KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MICRORNA MARKET SIZE, BY LIBRARY PREP KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MICRORNA MARKET SIZE, BY LIBRARY PREP KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MICRORNA MARKET SIZE, BY LIBRARY PREP KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MICRORNA MARKET SIZE, BY LIBRARY PREP KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MICRORNA MARKET SIZE, BY PROFILING KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MICRORNA MARKET SIZE, BY PROFILING KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICRORNA MARKET SIZE, BY PROFILING KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MICRORNA MARKET SIZE, BY PROFILING KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MICRORNA MARKET SIZE, BY PROFILING KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MICRORNA MARKET SIZE, BY PROFILING KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MICRORNA MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MICRORNA MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MICRORNA MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MICRORNA MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MICRORNA MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MICRORNA MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MICRORNA MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MICRORNA MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MICRORNA MARKET SIZE, BY CONSULTATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MICRORNA MARKET SIZE, BY CONSULTATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MICRORNA MARKET SIZE, BY CONSULTATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MICRORNA MARKET SIZE, BY CONSULTATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MICRORNA MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MICRORNA MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MICRORNA MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MICRORNA MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MICRORNA MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MICRORNA MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MICRORNA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MICRORNA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MICRORNA MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MICRORNA MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MICRORNA MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MICRORNA MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MICRORNA MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MICRORNA MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MICRORNA MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MICRORNA MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MICRORNA MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MICRORNA MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MICRORNA MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MICRORNA MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MICRORNA MARKET SIZE, BY CANCER DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MICRORNA MARKET SIZE, BY CANCER DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MICRORNA MARKET SIZE, BY CANCER DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MICRORNA MARKET SIZE, BY CANCER DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MICRORNA MARKET SIZE, BY CANCER DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MICRORNA MARKET SIZE, BY CANCER DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MICRORNA MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MICRORNA MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MICRORNA MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MICRORNA MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MICRORNA MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MICRORNA MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MICRORNA MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MICRORNA MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MICRORNA MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MICRORNA MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MICRORNA MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MICRORNA MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MICRORNA MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MICRORNA MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MICRORNA MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MICRORNA MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MICRORNA MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MICRORNA MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MICRORNA MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MICRORNA MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MICRORNA MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MICRORNA MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MICRORNA MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MICRORNA MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MICRORNA MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MICRORNA MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MICRORNA MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MICRORNA MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MICRORNA MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MICRORNA MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MICRORNA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MICRORNA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MICRORNA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MICRORNA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MICRORNA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MICRORNA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MICRORNA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MICRORNA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MICRORNA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MICRORNA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MICRORNA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MICRORNA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MICRORNA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MICRORNA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MICRORNA MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MICRORNA MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MICRORNA MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MICRORNA MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MICRORNA MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MICRORNA MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS MICRORNA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS MICRORNA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS MICRORNA MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS MICRORNA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS MICRORNA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS MICRORNA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS MICRORNA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA MICRORNA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA MICRORNA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA MICRORNA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA MICRORNA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MICRORNA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MICRORNA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA MICRORNA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA MICRORNA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA MICRORNA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA MICRORNA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MICRORNA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MICRORNA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE MICRORNA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE MICRORNA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE MICRORNA MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE MICRORNA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE MICRORNA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE MICRORNA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE MICRORNA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST MICRORNA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST MICRORNA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST MICRORNA MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST MICRORNA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST MICRORNA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST MICRORNA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST MICRORNA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA MICRORNA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA MICRORNA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA MICRORNA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA MICRORNA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA MICRORNA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA MICRORNA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC MICRORNA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC MICRORNA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC MICRORNA MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 341. ASIA-PACIFIC MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 342. ASIA-PACIFIC MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 343. ASIA-PACIFIC MICRORNA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 344. ASIA-PACIFIC MICRORNA MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 346. ASIA-PACIFIC MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 347. ASIA-PACIFIC MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 348. ASIA-PACIFIC MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 349. ASIA-PACIFIC MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 350. ASIA-PACIFIC MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 351. ASIA-PACIFIC MICRORNA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. ASIA-PA